Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).

Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.

Guidelines RSS feed

PHE COVID-19 vaccination guidance

A concise summary of guidance for healthcare professionals about the COVID-19 vaccination programme
Published: 22 Jul 2021

NICE atrial fibrillation guideline

A clear summary of NICE’s guideline on atrial fibrillation management
Published: 05 Jul 2021

NICE shared decision making guideline

Guidance on employing the collaborative process of involving a person and their healthcare professional to reach joint care decisions in primary care
Published: 24 Jun 2021

NICE autism management in children guideline

Guidance for offering support and management of children and young people with autism spectrum disorder
Published: 18 Jun 2021

PHE maintaining immunisation programmes during COVID-19

A brief summary providing the key points for primary care on maintaining immunisation programmes during the COVID-19 pandemic
Published: 11 Jun 2021

Self Care Forum sore throat fact sheet

A summary of recommendations for advising patients and the public on managing sore throat
Published: 11 Jun 2021

Visit the Guidelines website

Latest from PMLiVE on NICE, the SMC and the AWMSG

NICE recommends Ultomiris for NHS use in patients with rare blood disorders

NICE recommends Ultomiris for NHS use in patients with rare blood disorders 21 May 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Alexion’s long-acting C5 complement inhibitor Ultomiris for NHS use in patients with rare blood disorders. ... NICE has approved Ultomiris for the treatment of aHUS and

NICE recommends Keytruda for colorectal cancer patients with rare mutations

NICE recommends Keytruda for colorectal cancer patients with rare mutations 14 May 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Keytruda for NHS use as a first-line treatment for colorectal cancer patients with rare mutations. ... As a result, NICE recommends that Keytruda treatment should be

NICE sets out plans for ‘ambitious’ five-year strategy

NICE sets out plans for ‘ambitious’ five-year strategy 20 Apr 2021
NICE refocuses on reducing health inequalities and accelerating access to the latest and most effective treatments. ... learning will bring digital health in disease prevention and self care to the fore,” said Sharmila Nebhrajani, NICE chair.

Alexion and NICE agree confidential discount for Ultomiris use on the NHS

Alexion and NICE agree confidential discount for Ultomiris use on the NHS 16 Apr 2021
NICE said clinical evidence shows Ultomiris is as effective and safe as Alexion's older PNH drug Soliris. ... Compared with Alexion’s older drug, Ultomiris is a cost-effective use of NHS resources, concluded NICE.

NICE rejects Keytruda for advanced bladder cancer in final guidance

NICE rejects Keytruda for advanced bladder cancer in final guidance 18 Mar 2021
Following this rejection, MSD appealed the decision, although NICE has upheld its previous guidance not to recommend Keytruda as a second-line treatment for advanced bladder cancer patients. ... In a statement issued today, NICE said that although

More news from PMLiVE on NICE, the SMC and the AWMSG

MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.

To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Quick links